Cible’s smart drug platform overcomes platinum drug resistance
April 29, 2018
RXi Pharma developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform
May 1, 2018

Advances in Head and Neck Cancers

Head & Neck Cancer Report Launched

The first chapter of the Cancer Impact Guide includes an overall summary of the current approach to diagnosis and standard of care and profiles of companies. Visit the Head and Neck section of the Cancer Impact Guide. Several promising public  companies with catalysts on the horizon were identified including CEL-SCI, Soligenix and CytRx all who have become members of the Cancer Consortium, a global effort to increase collaboration of organizations of all types to advance progress in cancer.

Head and neck cancer researchers around the globe continue to make steady progress toward developing effective therapies.  companies and reports on their milestones. Here is our current snapshot of head and neck cancer research and development:

* CytRx Corporation (NASDAQ: CYTR) recently selected four new investigational-stage Linker-Activated Drug Release (LADR™) candidates for advancement toward clinical testing in cancer patients.  At the recent Annual Meeting of the American Association for Cancer Research,CytRx presented statistically significant breakthrough data for its albumin-binding ultra-high-potency LADR™ drug candidates.  CytRx’s LADR™ compounds demonstrate excellent long-term anti-tumor activity for head and neck cancers.

* CEL-SCI Corporation (NYSE: CVM) is developing immunotherapy products for the treatment of cancer and infectious diseases, based on the premise of boosting patients’ immune systems while they are still intact.  CEL-SCI’s lead investigational immunotherapy Multikine®treats patients who are newly diagnosed with head and neck cancer before they have undergone surgery, radiation, or chemotherapy. Multikine® has received an Orphan Drug designation from the FDA for treatment of head and neck cancer patients with advanced squamous cell carcinoma. They are well into the largest phase 3 cancer trial.

* Soligenix (NASDAQ: SNGX) is conducting a multi-center, double-blind, placebo-controlled Phase III clinical study of SGX942, its lead clinical Innate Defense Regulator candidate, which contains the active ingredient dusquetide.  The company is focusing the clinical trials on oral mucositis in head and neck cancer patients. Based on promising results from Phases I and II, SGX942 has been awarded Fast Track designation from the FDA for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients.

 Continue to the Head & Neck Chapter of Cancer Impact Guide>>

Leave a Reply

Your email address will not be published. Required fields are marked *